Abstract
Background: interferon beta (IFN-β) reduces relapse rate and disease progression in patients with the relapsing-remitting form of multiple sclerosis (RRMS). IFN-β may act by upregulating the expression of anti-inflammatory components of the immune system. Objectives: To determine whether weekly intramuscular (i.m.) injection of IFN-β1a had a short- or long-term effect on the expression of naturally occurring soluble factors that play an immunosuppressive role within the cytokine network. Materials and Methods: serum levels of interleukin-1 receptor antagonist (IL-1Ra), soluble tumor necrosis factor alpha receptor type I and type II (sTNF-αRI and sTNF-αRII), and soluble E-selectin (sE-Sel) were followed over time in ten patients with RRMS who were treated with weekly i.m. injections of 30 μg (= 6 MU) of IFN-β1a. Patient sera were sampled before, and 24, 48, 72, 96, and 168 hours after the first TFN-β1a injection (short-term), and then at 1, 3, 6, 9 and 12 months after therapy initiation (long-term); highly sensitive, commercially available ELISA tests were used. Results: serum levels of IL-1Ra, sTNF-αRI and sTNF-αRII, but not sE-Sel were significantly increased in both short- and long-term follow-up. Interestingly, IL-1Ra, sTNF-αRI and sTNF-αRII behaviors were completely different, suggesting that these naturally occurring immunoregulatory factors were differentially affected by IFN-β1a. Conclusion: our study demonstrates that weekly i.m. injection of 30 μg of IFN-β1a induces the expression of soluble mediators that may suppress the activities of pro-inflammatory cytokines such as IL-1 and TNF-α.
| Original language | English |
|---|---|
| Pages (from-to) | 81-85 |
| Number of pages | 5 |
| Journal | European Cytokine Network |
| Volume | 11 |
| Issue number | 1 |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Interferon beta
- Interleukin-1 receptor antagonist
- Multiple sclerosis
- Soluble E-selectin
- Soluble tumor necrosis factor alpha receptor
ASJC Scopus subject areas
- Cell Biology
- Immunology
Cite this
Interleukin-1 receptor antagonist, soluble tumor necrosis factor-a receptor type I and II and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-β1a. / Perini, Paola; Tiberio, Michela; Sivieri, Susanna; Facchinetti, Antonella; Biasi, Giovanni; Gallo, Paolo.
In: European Cytokine Network, Vol. 11, No. 1, 2000, p. 81-85.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Interleukin-1 receptor antagonist, soluble tumor necrosis factor-a receptor type I and II and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-β1a
AU - Perini, Paola
AU - Tiberio, Michela
AU - Sivieri, Susanna
AU - Facchinetti, Antonella
AU - Biasi, Giovanni
AU - Gallo, Paolo
PY - 2000
Y1 - 2000
N2 - Background: interferon beta (IFN-β) reduces relapse rate and disease progression in patients with the relapsing-remitting form of multiple sclerosis (RRMS). IFN-β may act by upregulating the expression of anti-inflammatory components of the immune system. Objectives: To determine whether weekly intramuscular (i.m.) injection of IFN-β1a had a short- or long-term effect on the expression of naturally occurring soluble factors that play an immunosuppressive role within the cytokine network. Materials and Methods: serum levels of interleukin-1 receptor antagonist (IL-1Ra), soluble tumor necrosis factor alpha receptor type I and type II (sTNF-αRI and sTNF-αRII), and soluble E-selectin (sE-Sel) were followed over time in ten patients with RRMS who were treated with weekly i.m. injections of 30 μg (= 6 MU) of IFN-β1a. Patient sera were sampled before, and 24, 48, 72, 96, and 168 hours after the first TFN-β1a injection (short-term), and then at 1, 3, 6, 9 and 12 months after therapy initiation (long-term); highly sensitive, commercially available ELISA tests were used. Results: serum levels of IL-1Ra, sTNF-αRI and sTNF-αRII, but not sE-Sel were significantly increased in both short- and long-term follow-up. Interestingly, IL-1Ra, sTNF-αRI and sTNF-αRII behaviors were completely different, suggesting that these naturally occurring immunoregulatory factors were differentially affected by IFN-β1a. Conclusion: our study demonstrates that weekly i.m. injection of 30 μg of IFN-β1a induces the expression of soluble mediators that may suppress the activities of pro-inflammatory cytokines such as IL-1 and TNF-α.
AB - Background: interferon beta (IFN-β) reduces relapse rate and disease progression in patients with the relapsing-remitting form of multiple sclerosis (RRMS). IFN-β may act by upregulating the expression of anti-inflammatory components of the immune system. Objectives: To determine whether weekly intramuscular (i.m.) injection of IFN-β1a had a short- or long-term effect on the expression of naturally occurring soluble factors that play an immunosuppressive role within the cytokine network. Materials and Methods: serum levels of interleukin-1 receptor antagonist (IL-1Ra), soluble tumor necrosis factor alpha receptor type I and type II (sTNF-αRI and sTNF-αRII), and soluble E-selectin (sE-Sel) were followed over time in ten patients with RRMS who were treated with weekly i.m. injections of 30 μg (= 6 MU) of IFN-β1a. Patient sera were sampled before, and 24, 48, 72, 96, and 168 hours after the first TFN-β1a injection (short-term), and then at 1, 3, 6, 9 and 12 months after therapy initiation (long-term); highly sensitive, commercially available ELISA tests were used. Results: serum levels of IL-1Ra, sTNF-αRI and sTNF-αRII, but not sE-Sel were significantly increased in both short- and long-term follow-up. Interestingly, IL-1Ra, sTNF-αRI and sTNF-αRII behaviors were completely different, suggesting that these naturally occurring immunoregulatory factors were differentially affected by IFN-β1a. Conclusion: our study demonstrates that weekly i.m. injection of 30 μg of IFN-β1a induces the expression of soluble mediators that may suppress the activities of pro-inflammatory cytokines such as IL-1 and TNF-α.
KW - Interferon beta
KW - Interleukin-1 receptor antagonist
KW - Multiple sclerosis
KW - Soluble E-selectin
KW - Soluble tumor necrosis factor alpha receptor
UR - http://www.scopus.com/inward/record.url?scp=0842278239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0842278239&partnerID=8YFLogxK
M3 - Article
VL - 11
SP - 81
EP - 85
JO - European Cytokine Network
JF - European Cytokine Network
SN - 1148-5493
IS - 1
ER -